Cabazitaxel Market Size, Share, Growth, and Global Industry Analysis by Type (Purity Above 99% and Other Purity), By Application (Age Below 65 and Age Above 65), Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights, and Forecast From 2024 To 2032

• 

   Request a Free Sample To Get More Information on this Market

CABAZITAXEL MARKET REPORT OVERVIEW

The global cabazitaxel market size was valued at USD 0.2 billion in 2023 and is projected to touch USD 0.33 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period. Asia-Pacific holds leading position in cabazitaxel market share in 2023.

Cabazitaxel is sold under the brand Jevtana, which is a semi-synthetic derivative of a natural taxoid. Taxane enriches microtubule stabilization and obstructs cellular mitosis and division. It prevents androgen receptor signaling by binding cellular microtubules and motor protein dynein. It is a microtubule inhibitor, and the fourth part is taxane to be sanctioned as a cancer treatment. It was advanced by Sanofi-Aventis and was accepted by the U.S. FDA for the cure of hormone-refractory prostate cancer on June 17, 2010. It is also accessible as a generic medication.

Cabazitaxel Treat cancer and men with metastatic castration-resistant prostate cancer. This is cancer that shakes the prostate gland that yields the liquid in semen (prostate fluid). It is used when cancer has spread to other parts of the body even with treatments to prevent the fabrication of testosterone or after surgical deduction of the testes.

Cabazitaxel is directed in grouping with prednisone for the cure of metastatic castration-resistant prostate cancer following docetaxel-based treatment. Cabazitaxel management reasons a reduction in plasma meditations presenting triphasic kinetics.

COVID-19 Impact: Halt on Operations to Obstruct Market Growth  

The global COVID-19 pandemic has been unprecedented and staggering, with cabazitaxel experiencing lower-than-anticipated/higher-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to the cabazitaxel market growth and demand returning to pre-pandemic levels once the pandemic is over.

The effects of the COVID-19 pandemic are already being felt on a global level, the global cabazitaxel market is noticeably influenced due to disruptions. In 2020, COVID-19 had a negative impact on many markets. Several countries went into lockdown. Many health institutions and clinics were turned into COVID-19 testing centers. Owing to the pandemic, elective procedures were temporarily halted and manufacturing companies closed their operations. With the sudden pandemic, all kinds of businesses observed disruptions. With many restrictions in the pandemic, different types of markets were negatively impacted. Logistics and patients’ reluctance to visit hospitals and clinics also halted the sale of cancer devices. 

LATEST TRENDS

"Technological Advancements to Push Market Progress"

The occurrence of prostate cancer, improvement in technologies and high unmet conditions are some of the major factors operating the market. The rising awareness of the people about cancer and its treatment will drive the cabazitaxel market growth during the forecast period. Prostate cancer at early stages generally does not indicate any signs. In the proceeding stages, the symptoms can be realized. Usually, early-stage prostate cancer needs a standard level of testosterone to cultivate, but hormone-refractory prostate cancer (HRPCA) does cultivate even when the testosterone level is low, and that’s why it is called Castrate-Restraint Prostate Cancer (CRPC). 

 Request a Free Sample To Get Analysis on Key Segments on this Market

CABAZITAXEL MARKET SEGMENTATION

• By Type

According to type; the market is divided into Purity Above 99% and Other Purity.

• By Application

Based on the application; the market is divided into Age Below 65 and Age Above 65.

DRIVING FACTORS

"Growing Incidences of Cancer to Drive Market Growth "

The rising number of prostate cancer patients and cardiac disorders is the key driver ensuing in the development of the market’s growth. The major factor prompting the growth rate of cabazitaxel market is the increasing healthcare spending. Moreover, increasing government backing and growing initiatives by public and private organizations to spread awareness about prostate cancer are the aspects that will develop the cabazitaxel market. Other aspects such as technical inventions allied with screening and tests and lifestyle changes will positively influence the market. Furthermore, improvements in genomics and proteomics and the increasing geriatric population will pillow the growth rate of prostate cancer. The appearance of sturdy pipeline medications and the existence of new prostate cancer therapies are the substantial factors that will intensify the growth rate of the market.

"Targeted Therapies to Foster Market Progress"

Targeted therapy is used for cancer treatment, in which the medications work by aiming at the precise genes or proteins that are present in the cancer cells. There are numerous types of targeted treatments for cancers, such as gene expression modulators, hormone therapies, angiogenesis inhibitors, apoptosis inducers, and signal transduction inhibitors. It is a promptly increasing in the field of research, and scientists are learning many new objectives. For example, the human epidermal growing factor receptor 2 protein (HER-2) is articulated at high levels on the exterior of some cancer cells. Several directed therapies are focused on HER-2, including trastuzumab (Herceptin), which is accepted to treat certain breast and stomach cancers that overexpress HER-2. 

RESTRAINING FACTORS

"High Cost to Impede Market Growth"

The high cost of the therapy, unreliable reimbursement plans and low life expectations are some of the factors that are acting as a restraint for the market. The premium pricing, which is delaying or making people unwilling to the treatment compounded with the reimbursement plans, which are also very undefined, is the main factor restraining the market.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market
•  

CABAZITAXEL MARKET REGIONAL INSIGHTS

"North America to Govern Market Due to Rise in Cancer Patients"

North America holds the largest part of the global cabazitaxel market share due to the rise in cancer patients. The U.S. is anticipated to hold substantial market share owing to the increasing prevalence of cancer, the presence of prominent players, growing research and development activities and satisfactory reimbursement plans. The U.S. Food and Drug Administration is captivating stages to improve the development of the cabazitaxel market by favoring drugs, which are in the experimental phase, thus fast-tracking the clinical advances. Corporations and research institutes are financing research and development activities.

Europe is expected to have a sizable market share. Companies are expected to emphasize hormone therapy sections such as antiandrogens in the prostate cancer therapeutics market in the region. The segment is anticipated to endure to be a potentially feasible segment for investment during the forecast period. The anticipated launch of products in the forecast period is expected to enhance the market growth. 

KEY INDUSTRY PLAYERS

"Key Players to Boost Demand Leading to Market Growth"

The report delivers information about the list of market players and their working in the industry. The information is collected and reported with proper research, technological developments, acquisitions, mergers, expanding production lines, and partnerships. Other aspects examined for the global chemotherapy devices market include companies producing and introducing new products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.

LIST OF TOP CABAZITAXEL COMPANIES

• Sanofi (France)
• Tapi Teva (Israel)
• Fuan Pharmaceutical Group (China)
• Fujian Yewpark Biological (China)

INDUSTRY DEVELOPMENT

• December 2020: EVER Pharma is happy to declare EU-wide advertising approval of Cabazitaxel for the cure of adult patients with metastatic prostate cancer. It is a more suitable construction that permits the safe treatment of this cytotoxic and saves time and costs compared to the presently accessible two vial system. 

REPORT COVERAGE

This research profiles a report with widespread studies that take into an explanation the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by examining the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.